Charles Schwab Investment Management Inc. Lowers Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Charles Schwab Investment Management Inc. reduced its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 4.8% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 787,490 shares of the company's stock after selling 40,055 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.77% of Intellia Therapeutics worth $9,182,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of NTLA. Whipplewood Advisors LLC purchased a new position in shares of Intellia Therapeutics during the fourth quarter valued at $40,000. KBC Group NV raised its holdings in shares of Intellia Therapeutics by 37.3% in the 3rd quarter. KBC Group NV now owns 3,753 shares of the company's stock valued at $77,000 after purchasing an additional 1,020 shares in the last quarter. Jones Financial Companies Lllp raised its holdings in shares of Intellia Therapeutics by 140.9% in the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company's stock valued at $45,000 after purchasing an additional 2,280 shares in the last quarter. Point72 DIFC Ltd bought a new position in shares of Intellia Therapeutics during the third quarter valued at approximately $151,000. Finally, AdvisorNet Financial Inc increased its holdings in shares of Intellia Therapeutics by 96.4% in the 4th quarter. AdvisorNet Financial Inc now owns 10,085 shares of the company's stock valued at $118,000 after acquiring an additional 4,950 shares during the period. 88.77% of the stock is owned by institutional investors.

Remove Ads

Insider Activity at Intellia Therapeutics

In related news, CEO John M. Leonard sold 26,807 shares of the company's stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the sale, the chief executive officer now owns 941,115 shares of the company's stock, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last 90 days, insiders sold 29,000 shares of company stock valued at $352,551. 3.20% of the stock is currently owned by insiders.

Intellia Therapeutics Trading Down 4.8 %

NTLA stock traded down $0.42 during mid-day trading on Wednesday, reaching $8.31. The company's stock had a trading volume of 4,111,320 shares, compared to its average volume of 2,135,077. The stock has a market cap of $860.23 million, a PE ratio of -1.53 and a beta of 1.97. The company's 50 day moving average is $10.05 and its two-hundred day moving average is $13.97. Intellia Therapeutics, Inc. has a fifty-two week low of $8.12 and a fifty-two week high of $28.23.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Morgan Stanley lowered Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and cut their target price for the company from $56.00 to $11.00 in a research note on Monday, January 27th. BMO Capital Markets lowered their target price on shares of Intellia Therapeutics from $70.00 to $50.00 and set an "outperform" rating for the company in a research note on Friday, January 10th. Barclays reduced their price objective on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Truist Financial reduced their price objective on Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Finally, StockNews.com raised shares of Intellia Therapeutics to a "sell" rating in a research note on Monday, March 3rd. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Intellia Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $37.56.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.